Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jacob H. Christensen"'
Autor:
Jacob H. Christensen, Pia V. Jensen, Ida B. Kristensen, Niels Abildgaard, Marianne Lodahl, Thomas Rasmussen
Publikováno v:
Haematologica, Vol 97, Iss 6 (2012)
Externí odkaz:
https://doaj.org/article/e868b9dd2703431eb69c519a58748136
Autor:
Marcela V. Maus, Matthew J. Frigault, Torben Barington, David M. Weinstock, Henrik J. Ditzel, Morten F. Gjerstorff, Jacob H. Christensen, Charlotte G. Nyvold, Oriane Cédile, Rikke S. Andersen, Bryan D. Choi, Andrea Schmidts, Lauren S. Riley, Rebecca C. Larson, Ana P. Castano, Amanda A. Bouffard, Selena J. Lorrey, Stefanie R. Bailey, Maria L. Cabral, Irene Scarfò, Maria Ormhøj
Supplementary Materials and Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4582e5857ca892ad3132a1732e1514a3
https://doi.org/10.1158/1078-0432.22471292.v1
https://doi.org/10.1158/1078-0432.22471292.v1
Autor:
Marcela V. Maus, Matthew J. Frigault, Torben Barington, David M. Weinstock, Henrik J. Ditzel, Morten F. Gjerstorff, Jacob H. Christensen, Charlotte G. Nyvold, Oriane Cédile, Rikke S. Andersen, Bryan D. Choi, Andrea Schmidts, Lauren S. Riley, Rebecca C. Larson, Ana P. Castano, Amanda A. Bouffard, Selena J. Lorrey, Stefanie R. Bailey, Maria L. Cabral, Irene Scarfò, Maria Ormhøj
Purpose:T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1dd747a9509cb3fb9a52f5ceb15ca80
https://doi.org/10.1158/1078-0432.c.6527840.v1
https://doi.org/10.1158/1078-0432.c.6527840.v1
Autor:
Jacob H. Christensen, Lars Qvortrup
Publikováno v:
Kausalitet og effektfuldhed ISBN: 9788775970056
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94ce19b5bc65558a8fbfd17fc7ed765b
https://doi.org/10.2307/j.ctv33jb5qs.3
https://doi.org/10.2307/j.ctv33jb5qs.3
Autor:
Jacob H. Christensen
Publikováno v:
Kausalitet og effektfuldhed ISBN: 9788775970056
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::698e26308ac68d64f438f47b3e6fc4e1
https://doi.org/10.2307/j.ctv33jb5qs.7
https://doi.org/10.2307/j.ctv33jb5qs.7
Autor:
Casper Thrane, Jacob H. Christensen
Publikováno v:
Kausalitet og effektfuldhed ISBN: 9788775970056
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddacccc5f63db1413454f808afbf9d11
https://doi.org/10.2307/j.ctv33jb5qs.8
https://doi.org/10.2307/j.ctv33jb5qs.8
Autor:
Mats Jerkeman, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Jacob H. Christensen, Hanne Kuitunen, Christian Winther Eskelund, Kirsten Groenbaek, Carsten Utoft Niemann, Christian H. Geisler, Arne Kolstad
Publikováno v:
Jerkeman, M, Hutchings, M, Räty, R, Wader, K F, Laurell, A, Kuitunen, H, Eskelund, C W, Groenbaek, K, Niemann, C U, Geisler, C H, Kolstad, A & Christensen, J H 2020, ' Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial ', Blood, vol. 136, no. Suppl. 1, pp. 36 . https://doi.org/10.1182/blood-2020-133298
Introduction: In spite of improvements in treatment of mantle cell lymphoma (MCL), this is still considered an incurable lymphoma entity, and the majority of patients eventually relapse. Ibrutinib is a very active agent in MCL, but in vitro has been